Clinical Trial Update: ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer [Phase 1]

View source ↗

Summary

A completed Phase 1 clinical trial evaluating Zometa (zoledronic acid) and Taxotere (docetaxel) in patients with metastatic prostate cancer (hormone-refractory)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Zometa (Zoledronic acid)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Metastatic Prostate Cancer | Phase 1 | Status: COMPLETED